Deborah A. Cera - Division of Compliance Center for Veterinary Medicine, FDA

Transcription

1 Deborah A. Cera - Division of Compliance Center for Veterinary Medicine, FDA 1 1

2 Databases RVIS Interagency Database TRIMS An Interactive Database Containing Information Obtained During FDA/State Inspections of Firms Involved/Responsible for Tissue Residue Violations. Attachment C Ensures Consistent Data Collection by both Federal and State Investigators Attachment G Drug Inventory 2 2

3 Dairy Cow Tissue Residues DRUG Total Percent Amikacin % Ampicillin % Ceftiofur * * % Dihydrostreptomycin % Fenbendazole % Florfenicol % Flunixin % Furazolidone % Gentamicin % Kanamycin % Lincomycin % Neomycin % 3

4 DRUG Total Percent Oxytetracycline % Penicillin % Phenylbutazone % Sulfachlorpyridazine % Sulfadiazine % Sulfadimethoxine % Sulfamethazine % Sulfathiazole % Tetracycline % Tilmicosin % Tulathromycin % Tylosin % Total

5 Additional Background It is an FDA priority to ensure the safety of animal-derived foods for human consumption FDA works with USDA and the States to monitor meat, poultry, and milk for unapproved or unsafe drug and chemical residues Although only 7.7% of the cattle slaughtered in the United States are adult dairy cattle they represent 67% of the tissue residue violations 5

6 Poor Practices Leading to Tissue Residues Drug residue violations in dairy cattle often result from poor husbandry practices on the farm. These practices include: Failure to maintain treatment records Failure to identify treated animals Failure to follow labeled withdrawal times Increasing the labeled dosage Increasing the length of treatment Giving the drug by an unapproved route of administration Drug given in unapproved species 6

7 Importance of Following Label Directions FDA approved animal drugs are labeled with the approved species, dosage, route of administration, frequency of use, condition to be treated, and meat and milk withdrawal times. When the directions for use on the approved label are followed, drug residues in meat and milk should not exceed the established drug tolerance. Good management practices at dairy farms include maintaining records of each animal treated, what drug it was treated with, when it was treated, and how it was treated, for example the route of administration, dosage and duration of treatment. Such records can be used by producers to ensure that treated cows put back into the milking string or sold for slaughter have met appropriate drug withdrawal times in order to prevent illegal drug residues in milk and meat. 7

8 Federal/State Cooperative Program FDA and the States currently participate in the National Conference on Interstate Milk Shipments (NCIMS). NCIMS is a voluntary coalition of regulators established to ensure the safety and wholesomeness of fresh milk in the U.S. FDA publishes the Grade A Pasteurized Milk Ordinance (PMO) as a model ordinance for States to adopt. 8

9 Current Milk Testing Requirements The PMO currently requires the sampling and testing of milk from bulk milk pick-up tankers when the milk is received at dairy plants. This sampling consists of commingled raw milk collected from various dairy farms. The PMO only requires that bulk milk pickup tankers be tested for the presence of at least four of six specific Beta Lactam class drugs. 9

10 Additional Compound Classes of Concern There are many other classes of drugs used on farms that are not tested for on a routine basis such as sulfonamide antibiotics like sulfadimethoxine, aminoglycoside drugs such as gentamicin, and anti-inflammatory drugs like flunixin. USDA/FSIS tissue residue data for calendar years indicates that over 50% of the violative drug residues in edible tissues reported in culled dairy cows are from drugs other than beta-lactam class drugs. 10

11 FDA s Concern FDA is concerned that the same poor practices that lead to drug residues in tissues might also be leading to drug residues in milk, especially of non-beta lactam drugs. In November 2010 FDA announced that it had developed a milk sampling assignment to determine whether our concern has merit. 11

12 Feedback FDA received feedback from State regulators and milk industry associations that because of the on-farm sample collection approach, the proposed plan would have a negative impact on producers and would cause milk to be dumped. FDA then participated in three listening sessions to seek input on revising the plan in an effort to avoid disruption to the milk supply. 12

13 Revised Sampling Plan In response to input received at these Listening Sessions, informal face to face meetings, and many individual concerns of our stakeholders the Agency has completely revised its sample assignment strategy. 13

14 Samples to be Collected As required in the Pasteurized Milk Ordinance (PMO), when certified bulk milk hauler/samplers collect raw milk samples, the Universal Sampling System is employed, whereby samples are collected every time milk is picked up at the farm. It is these Universal Samples that will be collected during this sampling assignment. 14

15 Revised Sampling Plan cont. FDA Investigators will visit laboratories holding Universal Samples and collect 900 samples from farms that have had tissue residue violations and 900 cohort samples from dairy farms not known to have had previous tissue residue violations. 15

16 Revised Sampling Plan cont. The origin of all samples collected, whether from the targeted group of known tissue residue violators or the cohort sample group, will be blinded utilizing an independent third party, the Institute for Food Safety and Health (IFSH) in Summit Argo, IL. The milk samples from all farms will be analyzed by one of three FDA laboratories for a broad range of drugs to determine if the milk contains violative drug residues. 16

17 How Will Targeted Farms be Selected? The sampling assignment will include the violators that have had tissue residues with the highest risk scores in culled dairy cows. The Risk Model takes into account the hazard associated with the drug, the likelihood of exposure, and the exposure level. FDA Investigators will be given an alphabetical list of selected violators by state of origin. 17

18 Methods A fully validated multi-class, multi-residue liquid chromatography/tandem mass spectrometry screening and confirmation method will be used to identify violative drug residues in milk. Additionally ELISA technology will be used to detect the presence of several aminoglycoside class drugs. All residues of drugs with established tolerances will be quantitated to confirm the level of drug present. 18

19 DRUG SAFE/TOLERANCE LEVEL (ppb) Ampicillin (AMP) 10 Cephapirin (CEPH) 20 Cloxacillin (CLOX) 10 Penicillin G (PEN G) 5 Erythromycin (ERY) 50 Tylosin (TYL) 50 Ciprofloxacin (CIP) None a Sarafloxacin (SAR) None a Chlortetracycline (CTC) 300 b Oxytetracycline (OTC) 300 b Tetracycline (TC) 300 b Doxycycline (DC) None a Sulfachloropyridazine (SCP) 10 Sulfadiazine (SDZ) 10 Sulfamerazine (SMR) 10 Sulfadimethoxine (SDM) 10 a no tolerance set for milk; method target level set at 100 ppb for VIR and TIL and DC; 10 ppb for TUL; and 5 ppb for CIP, SAR, CAP and FF b Tolerance includes sum and individual residues; method target levels set at 100 ppb each, the sum of the tetracylines present should not exceed 300 ppb. c Amount listed is a safe level from 9/27/05 FDA/CFSAN Milk Safety Branch Memo 19

20 DRUG SAFE/TOLERANCE LEVEL (ppb) Sulfamethazine (SMZ) 10 Suflaquinoxaline (SQX) 10 Sulfathiazole (STZ) 10 Tripelennamine (TRIP) 20 Thiabendazole (THBZ) 50 Flunixin (FLU) (Flunixinhydroxide) 2 Bacitracin (BAC) 500 Virginiamycin (VIR) 100 Tilmicosin (TIL) 100 Florfenicol 0 Chloramphenicol 0 Tulathromycin 0 Gentamicin 30 Neomycin 150 a no tolerance set for milk; method target level set at 100 ppb for VIR and TIL and DC; 10 ppb for TUL; and 5 ppb for CIP, SAR, CAP and FF b Tolerance includes sum and individual residues; method target levels set at 100 ppb each, the sum of the tetracylines present should not exceed 300 ppb. c Amount listed is a safe level from 9/27/05 FDA/CFSAN Milk Safety Branch Memo 20

21 Samples to be Collected cont. The State Milk Regulatory Agency shall be advised of this assignment and laboratories involved prior to the collection of any samples. The State Milk Regulatory Agency will be invited to participate in any sampling conducted in their state. Such participation is totally at the discretion of the State. 21

22 Violative Samples No enforcement actions will be taken in response to violative levels of residues in these samples because the purpose of the assignment is to determine if a problem exists. 22

23 Findings FDA will use the resulting data to inform the ongoing Milk Drug Residue Risk Assessment. Depending on the findings, FDA in active consultation with the National Conference on Interstate Milk Shippers, may expand the requirements for milk testing under the PMO to include additional compounds. FDA may also revise Compliance Program to routinely require the testing of farm bulk milk tanks during the inspection of a farm due to a violative tissue residue. 23

24 Timeline Prior to implementing the Milk Sampling Assignment the Agency will hold teleconferences with the Commissioners, Secretaries, and Directors of State Departments of Agriculture, and State Milk Regulatory Officials. The Agency will also notify the Executive Board of the National Conference on Interstate Milk Shippers and other affected stakeholders, i.e., Industry, Consumer Groups, etc., prior to starting the assignment. There is no specific timeline but the assignment is expected to start within the next few months and will take approximately 12 months to complete. 24

25 In Conclusion FDA s Milk Sampling Assignment is targeting the few members of an otherwise compliant industry in order to ensure that the public can have the utmost confidence in the dairy products that they consume. FDA continues to believe that the nation s milk supply is safe. Efforts such as this sampling assignment will ensure that potential problems, if they exist, remain minor and are quickly mitigated by education and enforcement, as appropriate. 25